NCT06469944 2026-03-16
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT06780111 2026-03-10
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05083481 2026-02-27
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT07214298 2026-02-06
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT04421820 2026-01-27
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06428409 2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06741644 2026-01-09
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT06703177 2025-12-03
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT07204574 2025-10-02
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Chang Gung Memorial Hospital
Phase 1/2 Recruiting
NCT06741020 2025-05-23
HAICI
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT06483555 2025-04-16
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting